<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364607</url>
  </required_header>
  <id_info>
    <org_study_id>MS.19.12.937.R1</org_study_id>
    <nct_id>NCT04364607</nct_id>
  </id_info>
  <brief_title>IM Neostigmine for Accelerating Bladder Emptying After CS by Spinal Anesthesia</brief_title>
  <official_title>Intramuscular Neostigmine for Accelerating Bladder Emptying After Cesarean Section by Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness of intramuscular (IM) 0.5 mg
      neostigmine for accelerating bladder emptying and preventing postoperative urine retention
      (POUR) after cesarean section (CS) performed under spinal anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be allowed to drink clear fluid up to 200 ml until 2 hours before induction of
      anesthesia. All women will be asked to urinate before transfer to the operating theatre. On
      arrival of the patient to operative theatre, intravenous (IV) cannula will be inserted and IV
      infusion of Ringer's acetate (20 ml/kg) will be given as a fluid preload. All participants
      will receive the standard intraoperative care and monitoring. After surgery, in the
      postoperative care unit, participants will receive either 0.5 mg IM neostigmine (study group)
      or IM NaCl 0.9% (control group).

      Urinary bladder ultrasound will be performed hourly until spontaneous micturition occurs. If
      POUR occurred (inability to void with at a bladder volume &gt; 600 ml detected by ultrasound),
      then they will be catheterized by closed envelope technique. The prolate ellipsoid method was
      used to measure urinary bladder volume based on the formula volume = length × width × height
      × 0.52 on a two-dimensional image. The duration of surgery, the amount of administered
      intraoperative fluid, and the urinary bladder volume before IM injection will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first voiding after IM injection</measure>
    <time_frame>Until 12 hours postoperatively</time_frame>
    <description>Time interval between IM injection of neostigmine or NaCl and occurrence of first voiding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first voiding after spinal anesthesia</measure>
    <time_frame>Until 12 hours postoperatively</time_frame>
    <description>Time interval between induction of spinal anesthesia and occurrence of first voiding</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Neostigmine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After surgery, in the postoperative care unit, participants will receive 0.5 mg IM neostigmine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After surgery, in the postoperative care unit, participants will receive IM NaCl 0.9% as a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Participants will receive 0.5 mg IM neostigmine</description>
    <arm_group_label>Neostigmine group</arm_group_label>
    <other_name>Epistigmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>Participants will receive IM NaCl 0.9% as a placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women undergoing elective CS under spinal anesthesia.

        Exclusion Criteria:

          -  Age &lt; 20 or &gt; 35 years.

          -  Height &lt; 150 or &gt; 180 cm or body mass index (BMI) &gt; 35 kg/m2.

          -  Active labor.

          -  Multifetal pregnancy.

          -  Fetal distress.

          -  Placenta previa.

          -  Vaginal bleeding or placental abruption.

          -  Medical conditions complicating or co-existing with pregnancy such as HELLP syndrome,
             thrombocytopenia, hepatic or renal impairment, cardiac disease or pulmonary edema or
             cyanosis.

          -  Urinary tract symptoms (frequency incontinence, enuresis. nocturia, hesitancy,
             urgency, weak stream, dysuria, and inability to empty the bladder fully).

          -  Contraindication for central neuraxial block.

          -  History of adverse reaction contraindications for Neostigmine.

          -  Refusal to undergo regional anesthesia.

          -  Surgical duration &gt; 1 hour.

          -  Intraoperative significant bleeding (&gt; 10% of blood volume).

          -  Any postoperative complications as eclampsia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aml Aljaml</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nermeen M Shams-Eldien, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Abdelhafez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed A Elnegery, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed S Abdelhafez, MD</last_name>
    <phone>+201144523366</phone>
    <email>msabdelhafez@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura University Hospital</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cesarean Section</keyword>
  <keyword>Spinal anesthesia</keyword>
  <keyword>Postoperative urine retention (POUR)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After publication and forever</ipd_time_frame>
    <ipd_access_criteria>Contact to corresponding author</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

